The final report of the Hunter Outcome Survey (HOS) confirms that idursulfase treatment for Mucopolysaccharidosis II provides a 10-year survival benefit and a 57.9% reduction in mortality risk compared to untreated cohorts, alongside sustained clinical improvements.